Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.

Rudin, C M; Holmlund, J; Fleming, G F; Mani, S; Stadler, W M; Schumm, P; Monia, B P; Johnston, J F; Geary, R; Yu, R Z; Kwoh, T J; Dorr, F A; Ratain, M J

Rudin, C M; Holmlund, J; Fleming, G F; Mani, S; Stadler, W M; Schumm, P; Monia, B P; Johnston, J F; Geary, R; Yu, R Z; Kwoh, T J; Dorr, F A; Ratain, M J.

Affiliation

Rudin CM; Section of Hematology/Oncology, University of Chicago Medical Center, Chicago, Illinois 60637-1470, USA. crudin@meecine.bsd.uchicago.edu

Clin Cancer Res ; 7(5): 1214-20, 2001 May.

Article in En | MEDLINE | ID: mdl-11350886

Subject(s)

Search on Google

Add to My VHL

XML

PubMed Links

Collection: 01-internacional Database: MEDLINE Main subject: Thionucleotides / Proto-Oncogene Proteins c-raf / Oligodeoxyribonucleotides, Antisense / Neoplasms / Antineoplastic Agents Limits: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Language: En Journal: Clin Cancer Res Journal subject: NEOPLASIAS Year: 2001 Document type: Article Affiliation country: Estados Unidos

Search on Google

Add to My VHL

XML

PubMed Links